** Shares of Neuren Pharmaceuticals NEU.AX rise 11% to A$13.92, their highest since June 13
** Stock is the top gainer on the benchmark index .AXJO
** Stock on track for best day since April 14 if gains hold
** Co receives patent application approval from U.S. regulator for the use of its NNZ-2591 drug to treat Pitt Hopkins syndrome, a neurodevelopmental condition
** Says patent's expiry date will be in April 2040
** Including day's moves, stock up 11.7% YTD
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((JasmeenAraIslam.Shaikh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。